Patient Experience Survey: Follicular Lymphoma Experience with/without Mosunetuzumab (Lunsumio) or Tafasitamab (Minjuvi) |
Introduction
Thank you for taking part in this online survey of patients & survivors. This survey will be used as part of Lymphoma Canada's submission to the Canadian Drug Agency (www.cda-amc.ca) and to INESSS (Institut national d'excellence en santé et en services sociaux), the Quebec equivalent. The CDA and INESSS assess cancer drugs for clinical and cost-effectiveness compared to other treatments that are currently available, and makes recommendations to provinces and territories to guide their drug funding decisions.
The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients. There are 2 seperate therapies that will soon be reviewed by CDA/INESSS including:
The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients. There are 2 seperate therapies that will soon be reviewed by CDA/INESSS including:
- Mosunetuzumab (also known as Lunsumio), which is a CD20×CD3 bispecific antibody, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
- Tafasitamab (also known as Minjuvi), which is an anti-CD19 monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.
- Tafasitamab (also known as Minjuvi), which is an anti-CD19 monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Your feedback is extremely important and may help improve access to this new drug for patients in Canada. The greater the response the better our data will be. The survey results may also be shared with other international groups who are submitting patient experience data for drug submissions. We will ensure no identifying information is shared.
YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY.
WE APPRECIATE INPUT FROM ALL PATIENTS WITH Follicular Lymphoma.
You can still participate if you have not been treated with Mosunetuzumab (Lunsumio) or Tafasitamab (Minjuvi).
If you have any questions, concerns, or technical difficulties while completing this survey please contact Lymphoma Canada at: info@lymphoma.ca
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.
If you have any questions, concerns, or technical difficulties while completing this survey please contact Lymphoma Canada at: info@lymphoma.ca
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.